VERICI DX PLC

Report Publication Announcement • Apr 24, 2023

National Storage Mechanism | Additional information

RNS Number : 1276X

Verici Dx PLC

24 April 2023

Verici Dx plc

("Verici Dx" or the "Company")

Final results timing

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it expects to report its final results for the year ended 31 December 2022 before the end of May 2023.

Verici Dx remains on track to report the full data readout from its Clarava™ validation trial during Q2 2023.

As indicated in the March progress update announcement, the Company had a cash balance of $9.81m as at 31 December 2022, which is expected to provide a cash runway until mid-2024.

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: +44 20 7496 3000
Aubrey Powell / Sam Butcher
Walbrook PR Limited	Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Stephanie Cuthbert / Sam Allen	Mob: +44 7980 541 893 / +44 7796 794 663 / 07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical wmanagement for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Clarava™, a pre-transplant prognosis test for the risk of early acute rejection, and Tutivia™, a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASESFWFEDSEEL